Article

Alopecia areata registry: an overview.

Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA.
Journal of Investigative Dermatology Symposium Proceedings (impact factor: 3.73). 11/2003; 8(2):219-21. DOI:10.1046/j.1087-0024.2003.00814.x pp.219-21
Source: PubMed

ABSTRACT The National Alopecia Areata Registry was awarded as a five-year contract by NIAMS to promote research on the genetic basis of alopecia areata. The registry is Web based and can be accessed online at http://www. AlopeciaAreata Registry.org. Samples of DNA, lymphoblast lines, and sera, as well as epidemiology and quality-of-life data, are being collected from well-characterized individuals, multiplex families, and sib pairs for future research studies and investigators.

0 0
 · 
0 Bookmarks
 · 
29 Views
  • Source
    Article: Advances in hair diseases.
    Maria Hordinsky
    Advances in Dermatology 02/2008; 24:245-59.
  • Source
    Article: Treatment of alopecia areata: "What is new on the horizon?".
    Maria K Hordinsky
    [show abstract] [hide abstract]
    ABSTRACT: New drug treatment opportunities based on the results of a genome-wide association study, which implicate T cell and natural killer (NK)-cell activation pathways, are leading to new approaches in future clinical trials of alopecia areata. Special attention is being given to the UL 16-binding protein (ULBP3) gene cluster on chromosome 6q25, as these genes make the NKG2D-activating ligand or signal that can trigger the NKG2D receptor, initiating an autoimmune response. A greater expression of ULBP3 has also been found in hair follicles in scalp biopsy specimens from patients with active disease. It is now postulated that the characteristic T cell "swarm of bees" infiltrate seen in alopecia areata is the result of T cells being attracted to the hair follicle by NKG2D-activating ligands. Future treatment approaches for alopecia areata include use of drugs that: (i) block the NKGD-activating ligand and NKG2D receptor interaction, (ii) halt activated T cells, or (iii) modification of the inflammatory cytokine network. Many drugs currently being used or being evaluated for other autoimmune diseases that work through these mechanisms might prove to be very effective in alopecia areata.
    Dermatologic Therapy 05/2011; 24(3):364-8. · 1.69 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

alopecia areata
 
AlopeciaAreata Registry.org. Samples
 
lymphoblast lines
 
National Alopecia Areata Registry
 
NIAMS
 
quality-of-life data
 
sib pairs
 
well-characterized individuals